FCF YoY
+394.94%
OCF YoY
+532.58%
Capex YoY
+90.96%
FCF Conversion Δ
-40.8 pp
Free cash flow bridge for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: $4.97B
FCF bridge breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | −$1.26B | — |
| Operating Cash Flow | $5.22B | +105.1% |
| Capital Expenditure | −$252.60M | -5.1% |
| Free Cash Flow | $3.71B | — |
- Prior Free Cash Flow−$1.26B
- Operating Cash Flow$5.22B
- Capital Expenditure−$252.60M
- Free Cash Flow$3.71B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement